<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585338</url>
  </required_header>
  <id_info>
    <org_study_id>NIH-LAMMP-ASLMS-2003-3086</org_study_id>
    <nct_id>NCT00585338</nct_id>
  </id_info>
  <brief_title>Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser</brief_title>
  <official_title>Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beckman Laser Institute University of California Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dermatologists have for many years treated vascular lesions by a variety of modalities
      including cryosurgery, electrotherapy, dermabrasion and radiation.

      It has been hypothesized that simultaneous delivery of these two wavelengths may provide
      safer, and in some cases more effective, vascular lesion removal.

      The Tandem laser is capable of emitting multiple cryogen spurts intermittently with multiple
      532/1064 nm laser pulses.This mode may reduce malformed blood vessels with a low incidence of
      long-term side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researcher can determine the blanching of vascular lesions after Tandem laser with
      multiple 532/1064 nm laser pulses treatment.

      The researcher will select one to four test sites spots for laser treatment. will be
      Different laser parameters can be used for each test site. The research will evaluate of the
      test sites at 6-12 weeks for bruising and blanching. Parameters of the test area with the
      greatest degree of blanching without adverse effects will be utilized for further treatment.
      If no test area is determined to have blanching without adverse effects, further test sites
      may be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laser treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Vascular Lesion</condition>
  <arm_group>
    <arm_group_label>Tandem 532/1064 nm Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tandem 532/1064 nm Laser</intervention_name>
    <description>Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser</description>
    <arm_group_label>Tandem 532/1064 nm Laser</arm_group_label>
    <other_name>Treatment of Vascular Lesions</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult age 18 years and older

          -  Diagnosis of vascular lesion

        Exclusion Criteria:

          -  Age &lt;18

          -  Pregnancy

          -  History of cutaneous photosensitivity

          -  Any therapy to the proposed treatment sites within the previous two months

          -  Current participation in any other investigational drug or device evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John S Nelson, M.D, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beckman Laser Institute University of California Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wangcun Jia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute University of California Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen Kelly, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beckman Laser Institute University of California Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beckman Laser Institute Medical and Surgical Clinic</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Beckman Laser Institute and Medical Center</investigator_full_name>
    <investigator_title>Wangcun Jia, PhD., Research Scientist</investigator_title>
  </responsible_party>
  <keyword>facial telangiectasia,</keyword>
  <keyword>leg vein telangiectasia</keyword>
  <keyword>Port Wine Stain birthmarks</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

